|
Abbate et al., "Carbonic Anhydrase Inhibitors: E7070, A Sulfonamide Anticancer Agent, Potently Inhibits Cytosolic Isozymes I and II, and Transmembrane, Tumor-Associated Isozyme IX," Bioorg. Med. Chem. Lett. 14:217-223, 2004.
|
|
Abdouh et al., "Early Upregulation of Kinin B1 Receptors in Retinal Microvessels of the Streptozotocin-Diabetic Rat," Br. J. Pharmacol. 140:33-40, 2003.
|
|
Aiello et al., "Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders," N. Engl. J. Med. 331:1480-1487, 1994.
|
|
Akita et al., "Protective Effect of C1 Esterase Inhibitor on Reperfusion Injury in the Rat Middle Cerebral Artery Occlusion Model," Neurosurgery 52:395-400, 2003.
|
|
Almdal et al., "The Independent Effect of Type 2 Diabetes Mellitus on Ischemic Heart Disease, Stroke, and Death: A Population-Based Study of 13,000 Men and Women with 20 Years of Follow-Up," Arch. Intern. Med. 164-1422-1426, 2004.
|
|
Arevalo et al., "Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema: Results from the Pan-American Collaborative Retina Study Group at 6-month Follow-up," Ophthalmology 114:743-750, 2007.
|
|
Bagella et al., "Cloning of Murine CDK9/PITALRE and Its Tissue-Specific Expression in Development," J. Cell. Physiol. 177:206-213, 1998.
|
|
Barber et al., "The Ins2Akita Mouse as a Model of Early Retinal Complications in Diabetes," Invest. Ophthalmol Vis. Sci. 46:2210-2218, 2005.
|
|
Bhoola et al., "Bioregulation of Kinins: Kallikreins, Kininogens, and Kininases," Pharm. Rev. 44:1-80, 1992.
|
|
Blasko et al., "How Chronic Inflammation Can Affect the Brain and Support the Development of Alzheimer's Disease in Old Age: The Role of Microglia and Astrocytes," Aging Cell 3:169-176, 2004.
|
|
Bloechle et al., "Inhibition of Bradykinin B2 Receptor Preserves Microcirculation in Experimental Pancreatitis in Rats," Am. J. Physiol. 247:G42-G51, 1998.
|
|
Bork et al., "Treatment of Acute Edema Attacks in Hereditary Angioedema with a Bradykinin Receptor-2 Antagonist (Icatibant)," J. Allergy. Clin. Immunol. 119:1497-1503, 2007.
|
|
Bos et al., "The Functional Integrity of the Serpin Domain of C1-Inhibitor Depends on the Unique N-Terminal Domain, as Revealed by a Pathological Mutant," J. Biol. Chem. 278:29463-29470, 2003.
|
|
Bouchie et al., "Natriuretic Factors and Nitric Oxide Suppress Plasminogen Activator Inhibitor-1 Expression in Vascular Smooth Muscle Cells. Role of cGMP in the Regulation of the Plasminogen System," Arterioscler. Thromb. Vasc. Biol. 18:1771-1779, 1998.
|
|
Bouchie et al., "P2Y Receptor Regulation of PAI-1 Expression in Vascular Smooth Muscle Cells," Arterioscler. Thromb. Vasc. Biol. 20:866-873, 2000.
|
|
Brenda Information for Plasma Kallikrein EC 3.4.21.34 < http://www.brenda-enzymes.org/php/flat-result.php4?ecno=3.4.21.34&organism-list=&Suchword=&UniProtAcc=#ORGANISM > visited Sep. 17, 2013.
*
|
|
Brenda Information for Plasma Kallikrein EC 3.4.21.34 < http://www.brenda-enzymes.org/php/flat—result.php4?ecno=3.4.21.34&organism—list=&Suchword=&UniProtAcc=#ORGANISM > visited Sep. 17, 2013.
*
|
|
Brenner et al., "Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy," N. Engl. J. Med. 345:851-860, 2001.
|
|
Brott et al., "Early Hemorrhage Growth in Patients with Intracerebral Hemorrhage," Stroke 28:1-5, 1997.
|
|
Caliezi et al., "C1-Esterase Inhibitor: An Anti-Inflammatory Agent and Its Potential Use in the Treatment of Diseases Other Than Hereditary Angioedema," Pharmacol. Rev. 52:91-112, 2000.
|
|
Campbell et al., "Towards Understanding the Kallikrein-Kinin System: Insights from Measurement of Kinin Peptides," Braz. J. Med. Biol. Res. 33:665-677, 2000.
|
|
Campbell, "The Kallikrein-Kinin System in Humans," Clin. Exp. Pharmacol. Physiol. 28:1060-1065, 2001.
|
|
Carugati et al., "C1-Inhibitor Deficiency and Angioedema," Mol. Immunol. 38:161-173, 2001.
|
|
Carvalho et al., J. Clin. Immunol. 27:246-56 (2007).
|
|
Casini et al., "Carbonic Anhydrase Inhibitors: Topically Acting Antiglaucoma Sulfonamides Incorporating Esters and Amides of 3- and 4-Carboxybenzolamide," Bioorg. Med. Chem. Lett. 13:2867-73, 2003.
|
|
Cecchi et al., "Carbonic Anhydrase Inhibitors. Design of Fluorescent Sulfonamides as Probes of Tumor-Associated Carbonic Anhydrase IX That Inhibit Isozyme IX-Mediated Acidification of Hypoxic Tumors," J. Med. Chem. 48:4834-4841, 2005.
|
|
Cecchi et al., "Carbonic Anhydrase Inhibitors: Synthesis and Inhibition of Cytosolic/Tumor-Associated Carbonic Anhydrase Isozymes I, II, and IX with Sulfonamides Derived from 4-Isothiocyanato-Benzolamide," Bioorg. Med. Chem. Lett. 14:5775-5780, 2004.
|
|
Chakravarty S. et al., J Mol Biol. 243(2):298-309 (1994).
|
|
Chao et al., "Experimental Therapy with Tissue Kallikrein Against Cerebral Ischemia," Front. Biosci. 11:1323-1327, 2006.
|
|
Chen et al., "B2 Bradykinin Receptor Immunoreactivity in Rat Brain," J. Comp. Neurol. 427:1-18, 2000.
|
|
Chen et al., "MEK1,2 Response Element Mediates Angiotensin II-Stimulated Plasminogen Activator Inhibitor-1 Promoter Activation," Blood 103:2636-2644, 2004.
|
|
Chen HC et al., Arterioscler Thromb Vasc Biol. 20(10):2297-302 (2000).
|
|
Chobanian et al., "The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report," JAMA 289:2560-2572, 2003.
|
|
Cholewinski et al., "Identification of B2 Bradykinin Binding Sites on Cultured Cortical Astrocytes," J. Neurochem. 57:1456-1458, 1991.
|
|
Cichon et al., "Increased Activity of Coagulation Factor XII (Hageman Factor) Causes Hereditary Angioedema Type III," Am. J. Human Genet. 79:1098-1104, 2006.
|
|
Ciulla et al., "Diabetic Retinopathy and Diabetic Macular Edema: Pathophysiology, Screening, and Novel Therapies," Diabetes Care 26:2653-2664, 2003.
|
|
Clermont et al., "Carbonic Anhydrase I (CA-1) Induces Retinal Vascular Permability In Vivo Through the Bradykinin (BK)/Kallikrein Pathway," Annual Meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, May 1-5, 2005, vol. 46, Suppl. S, p. 5183, 2005.
|
|
Clermont et al., "Role of Angiotensin II Type 1 Receptor in the Pathogenesis of Diabetic Retinopathy: Effects of Blood Pressure Control and Beyond," J. Hypertens. Supply 24:S73-80, 2006.
|
|
Dawson et al., "Pigment Epithelium-Derived Factor: A Potent Inhibitor of Angiogenesis," Science 285:245-248, 1999.
|
|
De La Cruz et al., "Pharmacological Approach to Diabetic Retinopathy," Diabetes-Metabolism Res. Reviews 20:91-113, 2004.
|
|
De Simoni et al., "Neuroprotection by Complement (C1) Inhibitor in Mouse Transient Brain Ischemia," J. Cereb. Blood Flow. Metab. 23:232-239, 2003.
|
|
Demchuk et al., "Serum Glucose Level and Diabetes Predict Tissue Plasminogen Activator-Related Intracerebral Hemorrhage in Acute Ischemic Stroke," Stroke 30:34-39, 1999.
|
|
Dennis et al., "Long-Term Survival After First-Ever Stroke: the Oxfordshire Community Stroke Project," Stroke 24:796-800, 1993.
|
|
Dennis et al., "Potent and Selective Kunitz Domain Inhibitors of Plasma Kallikrein Designed by Phage Display," J. Biol. Chem. 270:25411-25417, 1995.
|
|
Dewald et al., "Missense Mutations in the Coagulation Factor XII (Hageman Factor) Gene in Hereditary Angioedema With Normal C1 Inhibitor," Biochem. Biophys. Res. Commun. 343:1286-1289, 2006.
|
|
Dickneite, "Influence of C1-Inhibitor on Inflammation, Edema and Shock," Behring. Inst. Mitt. 93:299-305, 1993.
|
|
Dietrich et al., "CU-2010-A Novel Small Molecule Protease Inhibitor with Antifibrinolytic and Anticoagulant Properties," Anesthesiology 110:123-130, 2009.
|
|
Dietrich et al., "CU-2010—A Novel Small Molecule Protease Inhibitor with Antifibrinolytic and Anticoagulant Properties," Anesthesiology 110:123-130, 2009.
|
|
Ding-Zhou et al., "LF 16-0687 Ms, a Bradykinin B2 Receptor Antagonist, Reduces Ischemic Brain Injury in a Murine Model of Transient Focal Cerebral Ischemia," Br. J. Pharmacol. 139:1539-1547, 2003.
|
|
Easton et al., "Bradykinin Increases Permeability by Calcium and 5-Lipoxygenase in the ECV304/C6 Cell Culture Model of the Blood-Brain Barrier," Brain Res. 953:157-169, 2002.
|
|
Ebrahimian et al., "Dual Effect of Angiotensin-Converting Enzyme Inhibition on Angiogenesis in Type 1 Diabetic Mice," Arterioscler. Thromb. Vasc. Biol. 25:65-70, 2005.
|
|
Ellis et al., "Inhibition of Bradykinin- and Kallikrein-Induced Cerebral Arteriolar Dilation by a Specific Bradykinin Antagonist," Stroke 18:792-795, 1987.
|
|
Emanueli et al., "Local Delivery of Human Tissue Kallikrein Gene Accelerates Spontaneous Angiogenesis in Mouse Model of Hindlimb Ischemia" Circulation 103:125-132, 2001.
|
|
Emanueli et al., "Targeting Kinin B(1) Receptor for Therapeutic Neovascularization," Circulation 105:360-366, 2002.
|
|
Feener et al., "Angiotensin II Induces Plasminogen Activator Inhibitor-1 and -2 Expression in Vascular Endothelial and Smooth Muscle Cells," J. Clin. Invest. 95:1353-1362, 1995.
|
|
Feener et al., "Endothelial Dysfunction in Diabetes Mellitus: Role in Cardiovascular Disease," Heart Fail Monit. 1:74-82, 2001.
|
|
Feener et al., "Role of Protein Kinase C in Glucose- and Angiotensin II-Induced Plasminogen Activator Inhibitor Expression," Contrib. Nephrol. 118:180-187, 1996.
|
|
Feener et al., "Vascular Dysfunction in Diabetes Mellitus," Lancet 1:S19-13, 1997.
|
|
Ferrara, "Vascular Endothelial Growth Factor: Basic Science and Clinical Progress," Endocr. Rev. 25:581-611, 2004.
|
|
Folli et al., "Angiotensin II Inhibits Insulin Signaling in Aortic Smooth Muscle Cells at Multiple Levels. A Potential Role for Serine Phosphorylation in Insulin/Angiotension II Crosstalk," J. Clin. Invest. 100:2158-2169, 1997.
|
|
Funatsu et al., "Angiotensin II and Vascular Endothelial Growth Factor in the Vitreous Fluid of Patients with Diabetic Macular Edema and Other Retinal Disorders," Am. J. Ophthalmol. 133:537-543, 2002.
|
|
Funatsu et al., "Vitreous Levels of Interleukin-6 and Vascular Endothelial Growth Factor Are Related to Diabetic Macular Edema," Ophthalmology 110:1690-1696, 2003.
|
|
Funatsu et al., "Vitreous Levels of Vascular Endothelial Growth Factor and Intercellular Adhesion Molecule 1 Are Related to Diabetic Macular Edema," Ophthalmology 1112:806-816, 2005.
|
|
Gao et al. Diabetologia, 2003, 46:689-698.
*
|
|
Gao et al., "Angiotensin AT1 Receptor Antagonism Ameliorates Murine Retinal Proteome Changes Induced by Diabetes," J. Proteome Res. 8:5541-5549, 2009.
|
|
Gao et al., "Angiotensin II Stimulates Phosphorylation of an Ectodomain-Truncated Platelet-Derived Growth Factor Receptor-Beta and Its Binding to Class IA PI3K in Vascular Smooth Muscle Cells," Biochem. J. 397:337-344, 2006.
|
|
Gao et al., "Characterization of the Vitreous Proteome in Diabetes Without Diabetic Retinopathy and Diabetes With Proliferative Diabetic Retinopathy," J. Proteome Res. 7:2516-2525, 2008.
|
|
Gao et al., "Extracellular Carbonic Anhydrase Mediates Hemorrhagic Retinal and Cerebral Vascular Permeability Through Prekallikrein Activation," Nat. Med. 13:181-188, 2007.
|
|
Gao et al., "Kallikrein-Binding Protein Inhibits Retinal Neovascularization and Decreases Vascular Leakage," Diabetologia 46:689-698, 2003.
|
|
Garcia-Martin et al., "High Resolution pH(e) Imaging of Rat Glioma Using pH-Dependent Relaxivity," Mag. Res. Med. 55:309-315, 2006.
|
|
Gardner et al., "Astrocytes Increase Barrier Properties and ZO-1 Expression in Retinal Vascular Endothelial Cells," Invest. Ophthalmol. Vis. Sci. 38:2423-2427, 1997.
|
|
Giatromanolaki et al., "Expression of Hypoxia-Inducible Carbonic Anhydrase-9 Relates to Angiogenic Pathways and Independently to Poor Outcome in Non-Small Cell Lung Cancer," Cancer Res. 61:7992-7998, 2001.
|
|
Gimpl et al., "Bradykinin Receptors in Cultured Astrocytes from Neonatal Rat Brain Are Linked to Physiological Responses," Neurosci. Lett. 144:139-142, 1992.
|
|
Giusti et al., "Is Acetazolamide Effective in the Treatment of Diabetic Macular Edema? A Pilot Study," Int. Ophthalmol. 24:79-88, 2001.
|
|
Gonzalez et al., "Purification and Preliminary Characterization of a Plasma Kallikrein Inhibitor Isolated from Sea Hares Aplysia dactylomela Rang, 1828," Toxicon 43:219-223, 2004.
|
|
Gragoudas et al., "Pegaptanib for Neovascular Age-Related Macular Degeneration," N. Engl. J. Med. 351:2805-2816, 2004.
|
|
Griesbacher et al., "Involvement of Tissue Kallikrein but Not Plasma Kallikrein in the Development of Symptoms Mediated by Endogenous Kinins in Acute Pancreatitis in Rats," Br. J. Pharmacol. 137:692-700, 2002.
|
|
Hack et al., "Studies on the Contact System of Coagulation During Therapy with High Doses of Recombinant IL-2: Implications for Septic Shock," Thromb. Haemost. 65:497-503, 1991.
|
|
Hamajima et al., "Intranasal Administration of HIV-DNA Vaccine Formulated with a Polymer, Carboxymethylcellulose, Augments Mucosal Antibody Production and Cell-Mediated Immune Response," Clin. Immunol. Immunopathol. 88:205-210, 1998.
|
|
Hamano et al., J. Biol. Chem. 277:31154-62 (2002).
|
|
Hamdan et al., "Angiotensin-Converting Enzyme Inhibition Suppresses Plasminogen Activator Inhibitor-1 Expression in the Neointima of Balloon-Injured Rat Aorta," Circulation 93:1073-1078, 1996.
|
|
Han et al., "Increased Vascular Permeability in C1 Inhibitor-Deficient Mice Mediated by the Bradykinin Type 2 Receptor," J. Clin. Invest. 109:1057-1063, 2002.
|
|
Han Lee et al. "Approaches toward reversal of increased vascular permeability in C1 inhibitor deficient mice", Immun. Letts, 2003, 89:155-160.
*
|
|
Harris et al., "Soluble Tie2 and Flt1 Extracellular Domains in Serum of Patients with Renal Cancer and Response to Antiangiogenic Therapy," Clin. Can. Res. 7:1992-1997, 2001.
|
|
He et al., "Differential Regulation of Angiotensin II-Induced Expression of Connective Tissue Growth Factor by Protein Kinase C Isoforms in the Myocardium," J. Biol. Chem. 280:15719-15726, 2005.
|
|
Hess et al., "Cloning and Pharmacological Characterization of a Human Bradykinin (BK-2) Receptor," Biochem. Biophys. Res. Commun. 184:260-268, 1992.
|
|
Holder et al., "Pseudomonas elastase Acts as a Virulence Factor in Burned Hosts by Hageman Factor-Dependent Activation of the Host Kinin Cascade," Infect. Immun. 57:3345-3348, 1989.
|
|
Holter et al., J. Clin. Invest. 78:1513-22 (1986).
|
|
Horio et al., "Angiotensin AT(1) Receptor Antagonism Normalizes Retinal Blood Flow and Acetylcholine-Induced Vasodilatation in Normotensive Diabetic Rats," Diabetologia 47:113-123, 2004.
|
|
Houle et al., "Tissue Kallikrein Actions at the Rabbit Natural or Recombinant Kinin B2 Receptors," Hypertension 41:611-617, 2003.
|
|
Howl et al., "Bradykinin Receptors as a Therapeutic Target," Expert Opin. Ther. Targets 7:277-285, 2003.
|
|
Igic, "Kallikrein and Kininases in Ocular Tissues," Exp. Eye Res. 41:117-120, 1985.
|
|
Imamura et al., "Induction of Vascular Leakage and Blood Pressure Lowering Through Kinin Release by a Serine Proteinase from Aeromonas sobria," J. Immunol. 177:8723-8729, 2006.
|
|
Innocenti et al. "Carbonic Anhydrase Inhibitors: The First On-Resin Screening of a 4-Sulfamoylphenylthiourea Library," J. Med. Chem. 47:5224-5229, 2004.
|
|
International Preliminary Report on Patentability for PCT/US06/005395, issued Mar. 10, 2009.
|
|
International Preliminary Report on Patentability for PCT/US08/00998, issued Jul. 28, 2009.
|
|
International Search Report for PCT/US06/005395, completed Jun. 11, 2008, mailed Jul. 14, 2008.
|
|
International Search Report for PCT/US08/00998, completed Aug. 6, 2008, mailed Aug. 11, 2008.
|
|
International Search Report for PCT/US09/00609, completed Mar. 28, 2009, mailed Apr. 13, 2009.
|
|
International Search Report for PCT/US09/66437, completed Jan. 18, 2010, mailed Feb. 3, 2010.
|
|
Isawa et al., "A Mosquito Salivary Protein Inhibits Activation of the Plasma Contact System by Binding to Factor XII and High Molecular Weight Kininogen," J. Biol. Chem. 277:27651-27658, 2002.
|
|
Ito et al., "Regulation of Blood Pressure by the Type 1A Angiotensin II Receptor Gene," Proc. Natl. Acad. Sci. U.S.A. 92:3521-3525, 1995.
|
|
Iwaki et al., "Plasma Levels of Bradykinin Are Suppressed in Factor XII-Deficient Mice," Thromb. Haemost. 95:1003-1010, 2006.
|
|
Janghorbani et al., "Prospective Study of Type 1 and Type 2 Diabetes and Risk of Stroke Subtypes:The Nurses' Health Study," Diabetes Care 30:1730-1735, 2007.
|
|
Jeppesen et al., "Bradykinin Relaxation in Small Porcine Retinal Arterioles," Invest. Ophthalmol. Vis. Sci. 43:1891-1896, 2002.
|
|
Joseph et al., "Formation of Bradykinin: A Major Contributor to the Innate Inflammatory Response," Adv. Immunol. 86:159-208, 2005.
|
|
Joseph et al., "Heat Shock Protein 90 Catalyzes Activation of the Prekallikrein-Kininogen Complex in the Absence of Factor XII," Proc. Natl. Acad. Sci. U.S.A. 99:896-900, 2002.
|
|
Kakoki et al., "Diabetic Nephropathy Is Markedly Enhanced in Mice Lacking the Bradykinin B2 Receptor," Proc. Natl. Acad. Sci. U.S.A. 101:13302-13305, 2004.
|
|
Kamitani et al., "Evidence for a Possible Role of the Brain Kallikrein-Kinin System in the Modulation of the Cerebral Circulation," Circ. Res. 57:545-552, 1985.
|
|
Kato et al., "Identification and Characterization of the Plasma Kallikrein-Kinin System Inhibitor, Haemaphysalin, from Hard Tick, Haemaphysalis longicomis," Thromb. Haemost. 93:359-367, 2005.
|
|
Kazui et al., "Predisposing Factors to Enlargement of Spontaneous Intracerebral Hematoma," Stroke 28:2370-2375, 1997.
|
|
Kent et al., "Macular Oedema: The Role of Soluble Mediators," Br. J. Ophthalmol. 84:542-545, 2000.
|
|
King et al., "Pigment-Epithelium-Derived Factor-A Key Coordinator of Retinal Neuronal and Vascular Functions," N. Eng. J. Med. 342:349-351, 2000.
|
|
King et al., "Pigment-Epithelium-Derived Factor—A Key Coordinator of Retinal Neuronal and Vascular Functions," N. Eng. J. Med. 342:349-351, 2000.
|
|
Kissela et al., "Epidemiology of Ischemic Stroke in Patients with Diabetes: The Greater Cincinnati/Northern Kentucky Stroke Study," Diabetes Care 28:255-359, 2005.
|
|
Kita and Feener, "Kallikrein-kinin system in the eye," M. Bader (Ed). In: Kinins. New York: Walter de Gruyter GmbH & Co. KG; Chapter 11, pp. 171-186, Aug. 19, 2011.
|
|
Klein et al., "The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-Year Incidence and Progression of Diabetic Retinopathy and Associated Risk Factors in Type 1 Diabetes," Ophthalmology 105:1801-1815, 1998.
|
|
Kleinschnitz et al., "Targeting Coagulation Factor XII Provides Protection from Pathological Thrombosis in Cerebral Ischemia without Interfering with Hemostasis," J. Exp. Med. 203:513-518, 2006.
|
|
Knudsen et al., "Macular Edema Reflects Generalized Vascular Hyperpermeability in Type 2 Diabetic Patients with Retinopathy," Diabetes Care 25:2328-2334, 2002.
|
|
Kramer et al., Kidney Int'l. 55:2362-67 (1999).
|
|
Krogsaa et al., "The Blood-Retinal Barrier Permeability in Diabetic Patients," Acta. Ophthalmol. (Copenh.) 59:689-694, 1981.
|
|
Kuznetsova et al., "Activity of Tissue and Plasma Kallikrein and Level of Their Precursors in Eye Tissue Structures and Media of Healthy Rabbits," Vopr. Med. Khim. 37:79-82, 1991. (Russian language article, English language abstract provided.).
|
|
Lamark et al., "Expression of Active Human C1 Inhibitor Serpin Domain in Escherichia coli," Protein Expr. Purif. 22:349-358, 2001.
|
|
Lathem et al., "Potentiation of C1 Esterase Inhibitor by StcE, a Metalloprotease Secreted by Escherichia coli O157:H7," J. Exp. Med. 199:1077-1087, 2004.
|
|
Lawson et al., "Enhanced Dermal and Retinal Vascular Permeability in Streptozotocin-Induced Type 1 Diabetes in Wistar Rats: Blockade with a Selective Bradykinin B1 Receptor Antagonist," Regul. Pept. 124:221-224, 2005.
|
|
Liao et al., "Expression of Cell Surface Transmembrane Carbonic Anhydrase Genes CA9 and CA12 in the Human Eye: Overexpression of CA12 (CAXII) in Glaucoma," J. Med. Genet. 40:257-261, 2003.
|
|
Lin et al., "Inhibition of Nuclear Translocation of Transcription Factor NF-kappa B by a Synthetic Peptide Containing a Cell Membrane-Permeable Motif and Nuclear Localization Sequence," J. Biol. Chem. 270:14255-14258, 1995.
|
|
Liu et al., "Synergy Between A Plasminogen Cascade and MMP-9 in Autoimmune Disease," J. Clin. Invest. 115:879-887, 2005.
|
|
Lumenta et al., "Neuroprotective Effects of a Postischemic Treatment with a Bradykinin B2 Receptor Antagonist in a Rat Model of Temporary Focal Cerebral Ischemia," Brain Res. 1069:227-234, 2006.
|
|
Lund et al., "Plasminogen Activation Independent of uPA and tPA Maintains Wound Healing in Gene-Deficient Mice," EMBO J. 25:2686-2697, 2006.
|
|
Ma et al., "Expression and Cellular Localization of the Kallikrein-Kinin System in Human Ocular Tissues," Exp. Eye Res. 63:19-26, 1996.
|
|
Mahabeer et al., "Kallikrein and Kinin Receptor Genes," Pharmacol. Ther. 88:77-89, 2000.
|
|
Maier et al., "Intravitreal Injection of Specific Receptor Tyrosine Kinase Inhibitor PTK787/ZK222 584 Improves Ischemia-Induced Retinopathy in Mice," Graefes Arch. Clin. Exp. Opthalmol. 243:593-600, 2005.
|
|
Markland et al., "Iterative Optimization of High-Affinity Protease Inhibitors Using Phage Display. 2. Plasma Kallikrein and Thrombin," Biochemistry 35:8058-8067, 1996.
|
|
Marzouk et al., "Measurement of Extracellular pH, K(+), and Lactate in Ischemic Heart," Anal. Biochem. 308:52-60, 2002.
|
|
Matsuno et al., "Lack of Alpha 2-Antiplasmin Promotes Re-Endothelialization via Over-Release of VEGF After Vascular Injury in Mice," Blood 120:3621-3628, 2003.
|
|
Mayer et al., "Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage," N. Engl. J. Med. 352:777-785, 2005.
|
|
Mayer et al., "Treatment of Intracerebral Haemorrhage," Lancet Neurol. 4:662-672, 2005.
|
|
Miao et al., "Structural Elements of Kallistatin Required for Inhibition of Angiogenesis," Am. J. Physiol. Cell. Physiol. 284:C1604-C1613, 2003.
|
|
Miller et al., "Vascular Endothelial Growth Factor/Vascular Permeability Factor Is Temporally and Spatially Correlated with Ocular Angiogenesis in a Primate Model," Am. J. Pathol. 145:574-584, 1994.
|
|
Miura et al., "Transactivation of KDR/Flk-1 by the B2 Receptor Induces Tube Formation in Human Coronary Endothelial Cells," Hypertension 41:1118-1123, 2003.
|
|
Miyamoto et al., "Prevention of Leukostasis and Vascular Leakage in Streptozotocin-Induced Diabetic Retinopathy Via Intercellular Adhesion Molecule-1 Inhibition," Proc. Natl. Acad. Sci. U.S.A. 96:10836-10841, 1999.
|
|
Moreau et al., J Pharmacol Sci. 99:6-38 (2005).
|
|
Morgan et al., "Carbonic Anhydrase Inhibitors That Directly Inhibit Anion Transport by the Human Cl-/HCO3-Exchanger, AE1," Mol. Memb. Biol. 21:423-433, 2004.
|
|
Mulligan et al., Am. J. Pathol. 144:1008-15 (1994).
|
|
Nagelhus et al., "Carbonic Anhydrase XIV Is Enriched in Specific Membrane Domains of Retinal Pigment Epithelium, Muller Cells, and Astrocytes," Proc. Natl. Acad. Sci. U.S.A. 102:8030-8035, 2005.
|
|
Nagy et al., Angiogenesis 11:109-19 (2008).
|
|
Nakamura et al., "KRN633: A Selective Inhibitor of Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase That Suppresses Tumor Angiogenesis and Growth," Mol. Cancer Ther. 3:1639-1649, 2004.
|
|
Nakanishi et al., "Catalogue of Soluble Proteins in the Human Vitreous Humor: Comparison Between Diabetic Retinopathy and Macular Hole," J. Chromatogr. B Analyt. Tech. Biomed. Life Sci. 776:89-100, 2002.
|
|
Nakazawa et al., "Inhibition of Contact Activation by a Kininogen Peptide (HKH20) Derived from Domain 5," Int. Immunopharm. 2:1875-1885, 2002.
|
|
Neaton et al., "Treatment of Mild Hypertension Study. Final Results. Treatment of Mild Hypertension Study Research Group," JAMA 270:713-724, 1993.
|
|
Ng et al., "MBD2 Is a Transcriptional Repressor Belonging to the MeCP1 Histone Deacetylase Complex," Nat. Genet. 23:58-61, 1999.
|
|
Ni et al., "Overexpression of Kinin B1 Receptors Induces Hypertensive Response to des-Arg9-Bradykinin and Susceptibility to Inflammation," J. Biol. Chem. 278:219-225, 2003.
|
|
Ni et al., "Transcription Factor Nuclear Factor KappaB Regulates the Inducible Expression of the Human B1 Receptor Gene in Inflammation," J. Biol. Chem. 273:2784-2791, 1998.
|
|
Nishikiori et al., "Glial Cell-Derived Cytokines Attenuate the Breakdown of Vascular Integrity in Diabetic Retinopathy," Diabetes 56:1333-1340, 2007.
|
|
Noda et al., "Expression and Function of Bradykinin Receptors in Microglia," Life Sci. 72:1573-1581, 2003.
|
|
Nussberger et al., "Plasma Bradykinin in Angio-Oedema," Lancet 351:1693-1697, 1998.
|
|
Ogata et al., "Unbalanced Vitreous Levels of Pigment Epithelium-Derived Factor and Vascular Endothelial Growth Factor in Diabetic Retinopathy," Am. J. Ophthalmol. 134:348-353, 2002.
|
|
Ouchi et al., "Proteomic Analysis of Vitreous from Diabetic Macular Edema," Exp. Eye. Res. 81:176-182, 2005.
|
|
Pappalardo et al., "C1 Inhibitor Gene Expression in Patients with Hereditary Angioedema: Quantitative Evaluation by Means of Real-Time RT-PCR," J. Allergy Clin. Immunol. 114:638-644, 2004.
|
|
Pedersen et al., "Optic Nerve pH and PO2: The Effects of Carbonic Anhydrase Inhibition, and Metabolic and Respiratory Acidosis," Acta. Ophthalmol. Scand. 84:475-480, 2006.
|
|
Pelaez et al., "Low-Dose Angiotensin II Enhances Pressor Responses Without Causing Sustained Hypertension," Hypertension 42:798-801, 2003.
|
|
Pesquero et al., "Hypoalgesia and Altered Inflammatory Responses in Mice Lacking Kinin B1 Receptors," Proc. Natl. Acad. Sci. U.S.A. 97:8140-8145, 2000.
|
|
Phipps et al., "The Kallikrein-Kinin System in Diabetic Retinopathy: Lessons for the Kidney," Kidney Int. 73:1114-1119, 2008.
|
|
Phipps JA et al., Hypertension. 53(2):175-81 (2009).
|
|
Pickkers et al., Shock 24:508-12 (2005).
|
|
Pixley et al., "The Regulation of Human Factor XIIa by Plasma Proteinase Inhibitors," J. Biol. Chem. 260:1723-1729, 1985.
|
|
Plehwe et al., "Does Vitreous Fluorophotometry Reflect Severity of Early Diabetic Retinopathy?" Br. J. Opthalmol. 73:255-260, 1989.
|
|
Plesnila et al., "Role of Bradykinin B2 Receptors in the Formation of Vasogenic Brain Edema in Rats," J. Neurotrauma 18:1049-1058, 2001.
|
|
Quam et al., "VEGF-Initiated Blood-Retinal Barrier Breakdown in Early Diabetes," Invest. Ophthalmol. Vis. Sci. 42:2408-2413, 2001.
|
|
Qureshi et al., "Spontaneous Intracerebral Hemorrhage," N. Engl. J. Med. 344:1450-1460, 2001.
|
|
Raidoo et al., "Kinin Receptors on Human Neurons," J. Neuroimmunol. 77:39-44, 1997.
|
|
Raisler et al., "Adeno-associated Virus Type-2 Expression of Pigmented Epithelium-Derived Factor or Kringles 1-3 of Angiostatin Reduce Retinal Neovascularization," Proc. Natl. Acad. Sci. U.S.A. 99:8909-8914, 2002.
|
|
Reboul et al., "Proteolysis and Deglycosylation of Human C1 Inhibitor. Effect on Functional Properties," Biochem. J. 244:117-121, 1987.
|
|
Regoli et al., "B1 and B2 Kinin Receptors in Various Species," Immunopharmacology 36:143-147, 1997.
|
|
Regoli et al., "Receptors for Kinins: From Classical Pharmacology to Molecular Biology," Immunopharmacology 33:116-122, 1996.
|
|
Regoli et al., "Receptors for Kinins: From Classical Pharmacology to Molecular Biology," Immunopharmacology 33:24-31, 1996.
|
|
Relton et al., "CP-0597, A Selective Bradykinin B2 Receptor Antagonist, Inhibits Brain Injury in a Rat Model of Reversible Middle Cerebral Artery Occlusion," Stroke 28:1430-1436, 1997.
|
|
Rosamond et al., Heart Disease and Stroke Statistics—2007 Update: a Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation 115:e69-e171, 2007.
|
|
Sabourin et al., "Expression of Kinin B(1) Receptor in Fresh or Cultured Rabbit Aortic Smooth Muscle: Role of NF-Kappa B," Am. J. Physiol. Heart Circ. Physiol. 283:H227-H237, 2002.
|
|
Sasaki et al., "An Unexpected Inhibitory Activity of Kunitz-Type Serine Proteinase Inhibitor Derived from Boophilus Microplus Trypsin Inhibitor on Cathepsin L.," Biochem. Biophys. Res. Commun. 341:266-272, 2006.
|
|
Schneider et al., "Critical Role of Kallikrein in Hereditary Angioedema Pathogenesis: A Clinical Trial of Ecallantide, a Novel Kallikrein Inhibitor," J. Allergy. Clin. Immunol. 120:416-422, 2007.
|
|
Schoch et al., "Hypoxia-Induced Vascular Endothelial Growth Factor Expression Causes Vascular Leakage in the Brain," Brain 125:2549-2557, 2002.
|
|
Schousboe, "Binding of Activated Factor XII to Endothelial Cells Affects Its Inactivation by the C1-Esterase Inhibitor," Eur. J. Biochem. 270:111-118, 2003.
|
|
Schwaninger et al., "Bradykinin Induces Interleukin-6 Expression in Astrocytes Through Activation of Nuclear Factor-KappaB," J. Neurochem. 73:1461-1466, 1999.
|
|
Scott et al., "Kinetics of Inhibition of Human Plasma Kallikrein by a Site-Specific Modified Inhibitor Arg15-Aprotinin: Evaluation Using a Microplate System and Comparison with Other Proteases," Blood 69:1431-1436, 1987.
|
|
Scozzafava et al., "Carbonic Anhydrase Inhibitors: Synthesis of Sulfonamides Incorporating DTPA Tails and of Their Zinc Complexes with Powerful Topical Antiglaucoma Properties," Bioorg. Med. Chem. Lett. 11:575-582, 2001.
|
|
Selvarajan et al., "A Plasma Kallikrein-Dependent Plasminogen Cascade Required for Adipocyte Differentiation," Nat. Cell Biol. 3:267-275, 2001.
|
|
Senger et al., Science 219:983-85 (1983).
|
|
Shariat-Madar et al., "Identification and Characterization of Prolylcarboxypeptidase as an Endothelial Cell Prekallikrein Activator," J. Biol. Chem. 277:17962-17969, 2002.
|
|
Shariat-Madar et al., "Overexpression of Prolylcarboxypeptidase Enhances Plasma Prekallikrein Activation on Chinese Hamster Ovary Cells," Am. J. Physiol. Heart Circ. Physiol. 289:H2697-H2703, 2005.
|
|
Shariat-Madar et al., "Recombinant Prolylcarboxypeptidase Activates Plasma Prekallikrein," Blood 103:4554-4561, 2004.
|
|
Shia et al., "Conformational Lability in Serine Protease Active Sites: Structures of Hepatocyte Growth Factor Activator (HGFA) Alone and with the Inhibitory Domain from HGFA Inhibitor-1B," J. Mol. Biol. 346:1335-1349, 2005.
|
|
Shigematsu et al., "Bradykinin-Induced Proinflammatory Signaling Mechanisms," Am. J. Physiol. Heart Circ. Physiol. 283:H2676-H2686, 2002.
|
|
Siebeck et al., "Inhibition of Plasma Kallikrein with Aprotinin in Porcine Endotoxin Shock," J. Trauma 34:193-198, 1993.
|
|
Simo et al., "Free Insulin-Like Growth Factor 1 in the Vitreous Fluid of Diabetic Patients with Proliferative Diabetic Retinopathy: A Case-Control Study," Clin. Sci. (Lond.) 104:223-230, 2003.
|
|
Simo et al., "Hepatocyte Growth Factor in the Vitreous Fluid of Patients with Proliferative Diabetic Retinopathy: Its Relationship with Vascular Endothelial Growth Factor and Retinopathy Activity," Diabetes Care 27:287-288, 2004.
|
|
Sobey, "Bradykinin B2 Receptor Antagonism: A New Direction for Acute Stroke Therapy?" Br. J. Pharmacol. 139:1369-1371, 2003.
|
|
Song et al., "Hyperglycemia Exacerbates Brain Edema and Perihematomal Cell Death After Intracerebral Hemorrhage," Stroke 34:2215-2220, 2003.
|
|
Song et al., "Inhibition of Tumor Angiogenesis In Vivo by a Monoclonal Antibody Targeted to Domain 5 of High Molecular Weight Kininogen," Blood 104:2065-2072, 2004.
|
|
Spranger et al., "Release of the Angiogenesis Inhibitor Angiostatin in Patients with Proliferative Diabetic Retinopathy: Association with Retinal Photocoagulation," Diabetologia 43:1404-1407, 2000.
|
|
Srinivas et al., "Inhibition of Carbonic Anhydrase Activity in Cultured Bovine Corneal Endothelial Cells by Dorzolamide," Invest. Opthalmol. Vis. Sci. 43:3273-3278, 2002.
|
|
Stadnicki et al., "Selective Plasma Kallikrein Inhibitor Attenuates Acute Intestinal Inflammation in Lewis Rat," Dig. Dis. Sci. 41:912-920, 1996.
|
|
Stefansson et al., "Optic Nerve Oxygen Tension in Pigs and the Effect of Carbonic Anhydrase Inhibitors," Invest. Ophthalmol. Vis. Sci. 40:2756-2761, 1999.
|
|
Storini et al., "Selective Inhibition of Plasma Kallikrein Protects Brain from Reperfusion Injury," J. Pharmacol. Exp. Ther. 318:849-854, 2006.
|
|
Stratton et al., "Association of Glycaemia with Macrovascular and Microvascular Complications of Type 2 Diabetes (UKPDS 35): Prospective Observational Study," BMJ 321:405-412, 2000.
|
|
Sulikowski et al., "Alpha(1)-Proteinase Inhibitor Mutants with Specificity for Plasma Kallikrein and C1s but Not C1," Protein Sci. 11:2230-2236, 2002.
|
|
Sun et al., "[HCO3-]-Regulated Expression and Activity of Soluble Adenylyl Cyclase in Corneal Endothelial and Calu-3 Cells," BMC Physiol. 4:8, 2004.
|
|
Sun et al., "HCO3--Dependent Soluble Adenylyl Cyclase Activates Cystic Fibrosis Transmembrane Conductance Regulator in Corneal Endothelium," Am. J. Physiol. Cell Physiol. 284:C1114-C1122, 2003.
|
|
Sun et al., "Identification and Cloning of the Na/HCO3-Transporter (NBC) in Human Corneal Epithelium," Exp. Eye. Res. 7:287-295, 2003.
|
|
Supplemental European Search Report and European Search Opinion for EP 06735178, search completed Jul. 9, 2009, search and opinion mailed Jul. 20, 2009.
|
|
Supuran et al., "Carbonic Anhydrase Inhibitors," Med. Res. Rev. 23:146-189, 2003.
|
|
Suzuki et al., "Stromelysin-1 (MMP-3) Is Critical for Intracranial Bleeding After t-PA Treatment of Stroke in Mice," J. Thromb. Haemost. 5:1732-1739, 2007.
|
|
Suzuma et al., "Cyclic Stretch and Hypertension Induce Retinal Expression of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2: Potential Mechanisms for Exacerbation of Diabetic Retinopathy by Hypertension," Diabetes 50:444-454, 2001.
|
|
Svastova et al., "Hypoxia Activates the Capacity of Tumor-Associated Carbonic Anhydrase IX to Acidify Extracellular pH," FEBS Lett. 577:439-445, 2004.
|
|
Tans et al., "Autoactivation of Human Plasma Prekallikrein," J. Biol. Chem. 262:11308-11314, 1987.
|
|
The Diabetes Control and Complications Trial Research Group, "The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. The Diabetes Control and Complications Trial Research Group," N. Engl. J. Med. 329:977-986, 1993.
|
|
The NINDS t-PA Study Group, "Intracerebral Hemorrhage After Intravenous t-PA Therapy for Ischemic Stroke," Stroke 28:2109-2118, 1997.
|
|
Thuringer et al., "Rapid Transactivation of the Vascular Endothelial Growth Factor Receptor KDR/Flk-1 by the Bradykinin B2 Receptor Contributes to Endothelial Nitric-Oxide Synthase Activation in Cardiac Capillary Endothelial Cells," J. Biol. Chem. 277:2028-2032, 2002.
|
|
Tsuda Y. et al., Chem Pharm Bull (Tokyo) 46(3):452-7 (1998).
|
|
Tsuji et al., "Tissue Plasminogen Activator Promotes Matrix Metalloproteinase-9 Upregulation After Focal Cerebral Ischemia," Stroke 36:1954-1959, 2005.
|
|
Tuccillo et al., "Antitumor Activity of ZD6474, A Vascular Endothelial Growth Factor-2 and Epidermal Growth Factor Receptor Small Molecule Tyrosine Kinase Inhibitor, in Combination with SC-236, a Cyclooxygenase-2 Inhibitor," Clin. Cancer Res. 11:1268-1276, 2005.
|
|
UK Prospective Diabetes Study Group, "Tight Blood Pressure Control and Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 38," BMJ 37:703-713, 1998.
|
|
Unterberg et al., "Effects of Bradykinin on Permeability and Diameter of Pial Vessels In Vivo," J. Cereb. Blood Flow. Metab. 4:574-585, 1984.
|
|
van Doorn et al., "A Phase I Study of Recombinant Human C1 Inhibitor in Asymptomatic Patients with Hereditary Angioedema," J. Allergy Clin. Immunol. 116:876-883, 2005.
|
|
van Nieuw Amerongen Geerten et al., "Targets for Pharmacological Intervention of Endothelial Hyperpermeability and Barrier Function," Vascular Pharmacol. 39:257-272, 2002.
|
|
Veloso et al., "A Monoclonal Anti-Human Plasma Prekallikrein Antibody That Inhibits Activation of Prekallikrein by Factor XIIa on a Surface," Blood 70:1053-1062, 1987.
|
|
Verheul, "Vascular Endothelial Growth Factor and Its Inhibitors," Drugs Today (Barc.) 39 Suppl. C:81-93, 2003.
|
|
Villasante et al., J. Clin. Endocrinol. Metab. 92:314-321 (2007).
|
|
Vorstrup et al., "Effect of Acetazolamide on Cerebral Blood Flow and Cerebral Metabolic Rate for Oxygen," J. Clin. Invest. 74:1634-1639, 1984.
|
|
Wagner et al., "Activation of the Tissue Kallikrein-Kinin System in Stroke," J. Neurol. Sci. 202:75-76, 2002.
|
|
Wang et al., J. Infect. Dis. 202:991-1001 (2010).
|
|
Weber et al., "Unexpected Nanomolar Inhibition of Carbonic Anhydrase by COX-2-Selective Celecoxib: New Pharmacological Opportunities due to Related Binding Site Recognition," J. Med. Chem. 47:550-557, 2004.
|
|
Wilkinson-Berka, "Angiotensin and Bradykinin: Targets for the Treatment of Vascular and Neuro-Glial Pathology in Diabetic Retinopathy," Curr. Pharm. Des. 10:3313-3330, 2004.
|
|
Wilkinson-Berka, "Vasoactive Factors and Diabetic Retinopathy: Vascular Endothelial Growth Factor, Cyclooxygenase-2 and Nitric Oxide," Curr. Pharm. Des. 10:3331-3348, 2004.
|
|
Williams et al., "Epidemiology of Diabetic Retinopathy and Macular Oedema: A Systematic Review," Eye (Lond). 18:963-983, 2004.
|
|
Winum et al., "Carbonic Anhydrase Inhibitors: Inhibition of Transmembrane, Tumor-Associated Isozyme IX, and Cytosolic Isozymes I and II with Aliphatic Sulfamates," J. Med. Chem. 46:5471-5477, 2003.
|
|
Wistrand et al., "Carbonic Anhydrase Isoenzymes CA I and CA II in the Human Eye," Invest. Opthalmol. Vis. Sci. 27:419-428, 1986.
|
|
Witkin SR et al., JAMA. 251(19):2534-7 (1984).
|
|
Wojtkowski et al., "Three-Dimensional Retinal Imaging with High-Speed Ultrahigh-Resolution Optical Coherence Tomography," Ophthalmology 112:1734-1746, 2005.
|
|
Wolfensberger et al., "Membrane-Bound Carbonic Anhydrase in Human Retinal Pigment Epithelium," Invest. Ophthalmol. Vis. Sci. 35:3401-3407, 1994.
|
|
Wolfensberger, "The Role of Carbonic Anhydrase Inhibitors in the Management of Macular Edema," Documenta Ophthalmologica 97:387-397, 1999.
|
|
Written Opinion of the International Searching Authority for PCT/US06/005395, completed Jun. 11, 2008, mailed Jul. 14, 2008.
|
|
Written Opinion of the International Searching Authority for PCT/US08/00998, completed Aug. 6, 2008, mailed Aug. 11, 2008.
|
|
Written Opinion of the International Searching Authority for PCT/US09/00609, completed Mar. 28, 2009, mailed Apr. 13, 2009.
|
|
Written Opinion of the International Searching Authority for PCT/US09/66437, completed Jan. 18, 2010, mailed Feb. 3, 2010.
|
|
Xi et al., "Mechanisms of Edema Formation After Intracerebral Hemorrhage: Effects of Extravasated Red Blood Cells on Blood Flow and Blood-Brain Barrier Integrity," Stroke 32:2932-2938, 2001.
|
|
Xia et al., "Kallikrein Protects Against Ischemic Stroke by Inhibiting Apoptosis and Inflammation and Promoting Angiogenesis and Neurogenesis," Hum. Gene. Ther. 17:206-219, 2006.
|
|
Xia et al., "Postischemic Brain Injury Is Exacerbated in Mice Lacking the Kinin B2 Receptor," Hypertension 47:752-761, 2006.
|
|
Yamane et al., "Proteome Analysis of Human Vitreous Proteins," Mol. Cell. Proteomics 2:1177-1187, 2003.
|
|
Yang et al., "Mutant Carbonic Anhydrase 4 Impairs pH Regulation and Causes Retinal Photoreceptor Degeneration," Hum. Mol. Genet. 14:255-265, 2005.
|
|
Yanyali et al., "Bevacizumab (Avastin) for Diabetic Macular Edema in Previously Vitrectomized Eyes," Am. J. Ophthalmol. 144:124-126, 2007.
|
|
Zahedi et al., "C1 Inhibitor: Analysis of the Role of Amino Acid Residues Within the Reactive Center Loop in Target Protease Recognition," J. Immunol. 167:1500-1506, 2001.
|
|
Zahedi et al., "Unique C1 Inhibitor Dysfunction in a Kindred Without Angioedema. II. Identification of an Ala443→ Val Substitution and Functional Analysis of the Recombinant Mutant Protein," J. Clin. Invest. 95:1299-1305, 1995.
|
|
Zhang et al., Arch. Dermatol. Res. 297:425-29 (2006).
|
|
Zhou et al., "Kallistatin: A Novel Human Tissue Kallikrein Inhibitor. Purification, Characterization, and Reactive Center Sequence," J. Biol. Chem. 267:25873-25880, 1992.
|
